145 related articles for article (PubMed ID: 37211465)
1. Impact of biologic agents on body weight and obesity-related disorders in patients with psoriasis: A nationwide population-based cohort study.
Kim H; Hong JY; Cheong S; Kang JH
Obes Res Clin Pract; 2023; 17(3):210-217. PubMed ID: 37211465
[TBL] [Abstract][Full Text] [Related]
2. The effect of weight reduction on treatment outcomes in obese patients with psoriasis on biologic therapy: a randomized controlled prospective trial.
Al-Mutairi N; Nour T
Expert Opin Biol Ther; 2014 Jun; 14(6):749-56. PubMed ID: 24661040
[TBL] [Abstract][Full Text] [Related]
3. Change in body weight and body mass index in psoriasis patients receiving biologics: A systematic review and network meta-analysis.
Wu MY; Yu CL; Yang SJ; Chi CC
J Am Acad Dermatol; 2020 Jan; 82(1):101-109. PubMed ID: 31400455
[TBL] [Abstract][Full Text] [Related]
4. Persistence of treatment with biologics for patients with psoriasis: a real-world analysis of 16 545 biologic-naïve patients from the French National Health Insurance database (SNIIRAM).
Sbidian E; Mezzarobba M; Weill A; Coste J; Rudant J
Br J Dermatol; 2019 Jan; 180(1):86-93. PubMed ID: 29791721
[TBL] [Abstract][Full Text] [Related]
5. Real-world treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriasis.
Wu JJ; Pelletier C; Ung B; Tian M
J Med Econ; 2019 Apr; 22(4):365-371. PubMed ID: 30652520
[TBL] [Abstract][Full Text] [Related]
6. Persistence of second-line biologics in psoriasis after first-line biologic failure: a nationwide cohort study from the French health insurance database (SNDS).
Marcombes C; Penso L; Weill A; Dray-Spira R; Zureik M; Sbidian E
Br J Dermatol; 2023 Oct; 189(5):561-568. PubMed ID: 37479503
[TBL] [Abstract][Full Text] [Related]
7. The higher proportion of men with psoriasis treated with biologics may be explained by more severe disease in men.
Hägg D; Eriksson M; Sundström A; Schmitt-Egenolf M
PLoS One; 2013; 8(5):e63619. PubMed ID: 23691076
[TBL] [Abstract][Full Text] [Related]
8. First-Line Biologic Therapy and Obesity in Moderate-to-Severe Psoriasis: Results from the Prospective Multicenter Cohort Psobioteq.
Assan F; Tubach F; Arlegui H; Viguier M; Beylot-Barry M; Dupuy A; Beneton N; Joly P; Jullien D; Mahé E; Paul C; Richard MA; Bachelez H; Giboin C; Chosidow O; Sbidian E;
Dermatology; 2021; 237(3):338-346. PubMed ID: 33535213
[TBL] [Abstract][Full Text] [Related]
9. Biologic and Conventional Systemic Therapies Show Similar Safety and Efficacy in Elderly and Adult Patients With Moderate to Severe Psoriasis.
Garber C; Plotnikova N; Au SC; Sorensen EP; Gottlieb A
J Drugs Dermatol; 2015 Aug; 14(8):846-52. PubMed ID: 26267729
[TBL] [Abstract][Full Text] [Related]
10. Register-Based Evaluation of Relative Effectiveness of New Therapies: Biologics Versus Conventional Agents in Treatment of Psoriasis in Sweden.
Norlin JM; Carlsson KS; Persson U; Schmitt-Egenolf M
BioDrugs; 2015 Dec; 29(6):389-98. PubMed ID: 26670179
[TBL] [Abstract][Full Text] [Related]
11. Obesity and psoriasis: body weight and body mass index influence the response to biological treatment.
Puig L
J Eur Acad Dermatol Venereol; 2011 Sep; 25(9):1007-11. PubMed ID: 21492252
[TBL] [Abstract][Full Text] [Related]
12. Serious infections and tuberculosis in psoriasis patients receiving systemic therapy in Korea: a nationwide population-based cohort study.
Cho YA; Ahn J; Hong JY; Won S; Kim SM; Sung JY; Kim CY; Yu DA; Lee YW; Choe YB
Eur J Dermatol; 2023 Jun; 33(3):287-295. PubMed ID: 37594337
[TBL] [Abstract][Full Text] [Related]
13. Demographics and disease characteristics of patients with psoriasis enrolled in the British Association of Dermatologists Biologic Interventions Register.
Iskandar IY; Ashcroft DM; Warren RB; Yiu ZZ; McElhone K; Lunt M; Barker JN; Burden AD; Ormerod AD; Reynolds NJ; Smith CH; Griffiths CE
Br J Dermatol; 2015 Aug; 173(2):510-8. PubMed ID: 25989336
[TBL] [Abstract][Full Text] [Related]
14. Insurance Coverage of Biologics for Moderate-to-Severe Psoriasis: A Retrospective, Observational 5-Year Chart Review.
Abdelnabi M; Patel A; Rengifo-Pardo M; Ehrlich A
Am J Clin Dermatol; 2016 Aug; 17(4):421-4. PubMed ID: 27283586
[TBL] [Abstract][Full Text] [Related]
15. Body mass index in patients with moderate-to-severe psoriasis in Spain and its impact as an independent risk factor for therapy withdrawal: results of the Biobadaderm Registry.
Carrascosa JM; Vilavella M; Garcia-Doval I; Carretero G; Vanaclocha F; Daudén E; Gómez-García FJ; Herrera-Ceballos E; De la Cueva Dobao P; Belinchón I; Sánchez-Carazo JL; Alsina M; López-Estebaranz JL; Ferrán M; Peral F; Torrado R; Rivera R; Jiménez-Puya R; Mendiola MV; Ferrándiz C;
J Eur Acad Dermatol Venereol; 2014 Jul; 28(7):907-14. PubMed ID: 23848131
[TBL] [Abstract][Full Text] [Related]
16. Description of Patients Treated with Biologic Drugs as First-Line Systemic Therapy in the BIOBADADERM Registry Between 2008 and 2016.
Carretero Hernández G; Ferrándiz C; Rivera Díaz R; Daudén Tello E; de la Cueva-Dobao P; Gómez-García FJ; Herrera-Ceballos E; Belinchón Romero I; López-Estebaranz JL; Alsina Gibert M; Sánchez-Carazo JL; Ferrán Farrés M; González Quesada A; Carrascosa Carrillo JM; Llamas-Velasco M; Mendiola Fernández MV; Ruiz Genao D; Muñoz Santos C; García-Doval I; Descalzo MA;
Actas Dermosifiliogr (Engl Ed); 2018 Sep; 109(7):617-623. PubMed ID: 29887167
[TBL] [Abstract][Full Text] [Related]
17. Obesity, waist circumference, weight change and the risk of psoriasis in US women.
Kumar S; Han J; Li T; Qureshi AA
J Eur Acad Dermatol Venereol; 2013 Oct; 27(10):1293-8. PubMed ID: 23057623
[TBL] [Abstract][Full Text] [Related]
18. Serious infections among a large cohort of subjects with systemically treated psoriasis.
Dobry AS; Quesenberry CP; Ray GT; Geier JL; Asgari MM
J Am Acad Dermatol; 2017 Nov; 77(5):838-844. PubMed ID: 28917384
[TBL] [Abstract][Full Text] [Related]
19. Reducing patient copayment levels for topical and systemic treatments in plaque psoriasis as a case for evidence-based, sustainable pharmaceutical policy change in Greece.
Souliotis K; Golna C; Kani C; Litsa P
J Med Econ; 2016 Nov; 19(11):1021-1026. PubMed ID: 27207488
[TBL] [Abstract][Full Text] [Related]
20. Impact of obesity and smoking on psoriasis presentation and management.
Herron MD; Hinckley M; Hoffman MS; Papenfuss J; Hansen CB; Callis KP; Krueger GG
Arch Dermatol; 2005 Dec; 141(12):1527-34. PubMed ID: 16365253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
